Standout Papers

Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Le... 2009 2026 2014 2020 494
  1. Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer (2009)
    José Baselga, Semiglazov Vf et al. Journal of Clinical Oncology

Citation Impact

1 by Nobel laureates 28 from Science/Nature 72 standout
Sub-graph 1 of 20

Citing Papers

The central role of DNA damage in the ageing process
2021 StandoutNature
mTOR at the nexus of nutrition, growth, ageing and disease
2020 Standout
6 intermediate papers

Works of Michael Stumm being referenced

A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual PI3K/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors: Final DE results.
2015
Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
2008
and 1 more

Author Peers

Author CNC HA Information Systems Molecular Biology Oncology Last Decade Papers Cites
Michael Stumm 698 444 326 1056 609 59 2.6k
Alka Indurkhya 2 1 4 16 15 590
Gevdeep Bhabra 1 65 6 4 440
K.G. Mäler 1 3 234
Susan Kemball‐Cook 4 8 936
Wen Cheng 1 4 20 359

All Works

Loading papers...

Rankless by CCL
2026